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Metastasis is a major clinical issue and results in poor prognosis for most cancers. The Junctional
Adhesion Molecule-C (JAM-C) expressed by B16 melanoma and endothelial cells has been involved
in metastasis of tumor cells through homophilic JAM-C/JAM-C trans-interactions. Here, we show
that JAM-B expressed by endothelial cells contributes to murine B16 melanoma cells metastasis
through its interaction with JAM-C on tumor cells. We further show that this adhesion molecular
pair mediates melanoma cell adhesion to primary Lung Microvascular Endothelial Cells and that
it is functional in vivo as demonstrated by the reduced metastasis of B16 cells in Jam-b deﬁcient
mice.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
During hematogenous metastatic dissemination, circulating tu-
mor cells that have detached from primary tumor interact with
vascular endothelial cells. Such an interaction is primordial for
the invasion of new organs by tumors cells and uses molecular
mechanisms that are similar to those used for leukocyte transen-
dothelial migration. In this context, adhesion molecules involved
in leukocyte transmigration and interaction with endothelial cells
are good candidates to mediate invasiveness and metastatic prop-
erty of tumor cells.
The Junctional Adhesion Molecule (JAM) family belongs to the
immunoglobulin superfamily and is composed of three classical
members JAM-A, JAM-B and JAM-C. By its expression in endothelial
tight junction, JAM-C has been involved in leukocyte transmigra-
tion and in the formation and the maintenance of intercellular con-
tact, suggesting that it could contribute to endothelial junction
remodeling [1]. Previous studies from the laboratory have shownchemical Societies. Published by E
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r (M.-L. Arcangeli), michel.that blocking antibody directed against JAM-C can interfere
in vivo with tumor growth and can abrogate in vivo and ex vivo
angiogenesis [2]. In addition, jam-c overexpression in KLN205 car-
cinoma cell line has been shown to increase cell migration through
integrin activation suggesting a cell autonomous function for JAM-
C in tumor cells [3]. This has been indirectly conﬁrmed through
two independent studies that have correlated expression of JAM-
C in ﬁbrosarcoma and melanoma cells with increased invasive
properties and metastatic potential of tumor cells [4,5]. More re-
cently, H.F. Langer and colleagues have shown that JAM-C contrib-
utes to B16 melanoma cell metastasis into the lungs [6]. This
occurs through JAM-C homophilic interactions between B16 mela-
noma cells and endothelial cells as demonstrated by reduced lung
metastasis of B16 cells in mice conditionally deleted for JAM-C
expression in endothelial cells. However, one could not exclude
that other molecular interactions between JAM-C expressed on tu-
mor cells and additional ligands contribute to metastasic dissemi-
nation of B16 melanoma cells. Indeed, JAM-C has been shown to
interact with the leukocyte integrins aMb2 and aXb2 and is known
to trans-interact with itself or JAM-B [7–10]. Conversely, JAM-B has
been shown to interact with cells expressing the integrin a4b1 if
JAM-C is coexpressed with this integrin on target cells [11]. Finally,
previous studies of the laboratory have established that JAM-C pre-
sents more afﬁnity for JAM-B than for JAM-C in cell free system
using recombinant soluble molecules and dynamic light scatteringlsevier B.V. All rights reserved.
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if JAM-C also contributes to B16 melanoma cell metastasis through
its interaction with JAM-B expressed by endothelial cells. To this
end, we used siRNA knock-down approaches in B16F10 cells, as
well as Jam-b deﬁcient mice to demonstrate the contribution of
vascular JAM-B to metastatic dissemination of melanoma cells
in vivo.
2. Materials and methods
2.1. Mice
Generation and phenotype of Jam-b deﬁcient mice were previ-
ously described [13]. Mice used in the present study were back-
crossed for more than six generations on C57Bl/6 background.
C57BL/6 mice were purchased at Janvier Laboratory. All experi-
ments were performed in agreement with the French Guidelines
for animal handling.
2.2. Cell lines, antibodies, reagents and ﬂow cytometry
B16F10 cell line was obtained from ATCC (CRL-6475). When
applicable, recombinant soluble forms of mouse JAM-B (sol-JAM-
B) and JAM-C (sol-JAM-C) (R&D system) were revealed with goat-
anti-humanFC secondary antibodies coupled to Phycoerythrin
(PE) (Jackson Immunoresearch). Polyclonal rabbit anti-mouse anti-
bodies directed against JAM-B (pAb 829) and JAM-C (pAb 501),
monoclonal rat anti-mouse antibody (13H33) directed against
JAM-C were produced in the laboratory. Goat-anti-Rabbit-PE and
Goat-anti-Rat-PE respectively (Jackson Immunoresearch) were
used as secondary antibodies. Flow cytometry was done with a
BD-LSR2 SORP (laser 405, 488, 561 and 633, BD Bioscience) and
data analyses were performed with the BD-DIVA software (BD Bio-
science) or the FlowJo software. For competition experiments,
B16F10 cells were ﬁrst incubated with 13H33 (1 lg/mL) or control
mAb for 20 min at 4 C, washed and further incubated with sol-
JAM-B (1 lg/mL) or with pAb 501 against JAM-C (1/250) forFig. 1. JAM-B expression in murine lungs. Pictures showing the pattern of
expression of PECAM-1 (red), JAM-B (green), and DAPI (blue) on lung cryosections.
The merge picture shows partial colocalization between JAM-B and PECAM-1
staining on lung vessel.20 min at 4 C. After washing, the binding of sol-JAM-B or pAb
501 was revealed using anti-hFC-PE and anti-Rabbit-PE
respectively.
2.3. siRNA experiments
B16F10 cells were transfected with siRNA Control or siRNA di-
rected against Jam-c (smart pool Dharmacon) using Lipofectamin
RNAimax according to manufacturer’s protocol (Lifetechnologies).
JAM-C down-regulation was quantiﬁed by ﬂow cytometry 48 h
after transfection.
2.4. In vivo homing assay
B16F10 siRNA Control cells and B16F10 siRNA Jam-c cells were
labeled separately with PKH26 (red) and PKH67 (green) ﬂuores-
cent linker kit (SIGMA) according to manufacturer’s protocol. Cells
were mixed in 1:1 ratio and injected into mice (2.106 cells/200 lL
NaCl per mice). Each series contained six injected mice and a con-
trol (NaCl-only injected mouse). A ﬁrst series of animals were sac-
riﬁced 3 h later. For each mouse, lungs were cut in very small
pieces, digested at 37 C 45 min in collagenase I (1 mg/ml, Sigma)
washed in PBS-EDTA 1.25 mM 2%FCS and resuspended in PBS-
EDTA 1.25 mM 2%FCS. All preparations were clariﬁed of red blood
cells using red cell lysis (ACK lysing Buffer, Invitrogen). Cell sus-
pensions were prepared in the same volume for the two time
points and the same numbers of cells were analyzed allowing qual-
itative comparison of cell numbers. Cells in each organ were ana-
lyzed for expression of green and red ﬂuorescence by FACSFig. 2. Anti-JAM-C blocking antibody prevents JAM-B/JAM-C interaction. (A) Left
panel: Flow cytometry proﬁles showing the binding of recombinant soluble (rs)
forms of JAM-B (plain line) or JAM-C (dotted line) to B16F10 melanoma cells
preincubated with 9B5 isotype control mAb. Unstained control overlapped with
soluble JAM-C staining and is not shown. The grey ﬁlled proﬁle shows the binding of
sol-JAM-B to B16F10 cells preincubated with the blocking 13H33 anti-JAM-C mAb
(ﬁlled line). Right panel: Histogram showing the Relative Fluorescence Intensity
(RFI) obtained with sol-JAM-B under the indicated conditions. (B) Left panel: Flow
cytometry proﬁles showing the staining of B16F10 cells preincubated with the 9B5
isotype control mAb using rabbit 501 pAb against JAM-C (plain line) as compared to
preimmune serum (dotted line). The grey ﬁlled proﬁle shows the staining obtained
with the rabbit 501 pAb against JAM-C on B16F10 cells preincubated with the
blocking 13H33 anti-JAM-C mAb (ﬁlled line). Right panel: Histogram showing
the Relative Fluorescence Intensity (RFI) obtained with the rabbit pAb 501 under
the indicated conditions.
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Fig. 3. JAM-C dependent adhesion of B16F10 cells to JAM-B. (A) Histograms show
the adhesion of B16F10 cells in control conditions (plastic), sol-JAM-B or sol-JAM-C
as indicated. Results show one out of three experiments and are expressed as
percent of input. ⁄⁄⁄, p < 0,001. (B) Flow cytometry proﬁle showing JAM-B
expression on primary Lung Microvascular Endothelial Cells (LMECs). (C) Flow
cytometry proﬁles showing the expression of JAM-C on B16F10 cells upon
transfection with the indicated siRNA. siRNA against Jam-c results in loss of surface
JAM-C expression. (D) Histograms show the adhesion of control B16F10 cells or
B16F10 cells silenced for Jam-c expression to LMECs. Results show one out of three
experiments and are expressed as percent of input. ⁄⁄⁄, p < 0,001.
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Jose, CA, USA). Standard deviation obtained for the H0 is made on
three independent ﬂow cytometry measurements of the injected
cell ratios at time zero (when cells are injected), 1.5 h later and
when mice are sacriﬁced (H3 in vitro). This allows us to exclude
that siRNA Jam-c or siRNA Control induces apoptosis of B16F10
cells that will change the H0 ratio of non-injected cells over time.
Standard deviation obtained in vivo after 3 h (H3) is calculated
from the experimental groups of six mice. When several experi-
ments were pooled, injected ratios at time zero were normalized
to 1.
2.5. LMEC preparation
Lung Microvascular Endothelial Cells were prepared as previ-
ously described [12]. Brieﬂy, lungs were cut in small pieces and di-
gested with collagenase I (1 mg/mL) diluted in Ham/F12 medium
for 30 min at 37 C. Collagenase digestion was stopped by adding
Ham/F12 supplemented with 20% FCS and washed twice. Lung
cells were resuspended in complete medium (HAM/F12 20% FCS
supplemented with ECGS (100 lg/mL, Sigma) and Heparin (10 U/
mL, Sigma). After 2 days of culture, myeloid cells were removed
by magnetic cell sorting using 2/4.G2 antibody and sheep anti-rat
Dynal beads (Dynal, Lifetechnologies). To insure cell purity, few
days after the negative selection, endothelial cells were positively
puriﬁed using magnetic cell sorting, GC51 (anti-PECAM) and 3C4
(anti-ICAM2) antibodies and sheep-anti-Rat Dynal beads (Dynal,
Lifetechnologies).
2.6. Adhesion assays
Ninety six ﬂat well plates (MaxiSorp, Nunc), were coated over-
night at 4 C with 20 lg/mL of recombinant sol-JAM-B or sol-JAM-
C. Wells were washed twice in PBS 1X and saturated with HBSS 5%
BSA for 1 h at 37. Then, 5  105 B16F10 cells resuspended in200 ll of HBSS 5% BSA were allowed to adhere for one hour. Plates
were washed 3 times with PBS and adherent cells were removed
with trypsin EDTA (Invitrogen), washed once in PBS EDTA1.25 mM
2% FCS and resuspended in PBS EDTA1.25 mM 2% FCS. Absolute
numbers were evaluated using the HTS coupled to the BD-LSR2
SORP (BD Bioscience).
For adhesion assays using the LMEC cell line, LMEC cells were
plated on 96 ﬂat bottom well plates, at the concentration of
5000 cells/well 1 day before the assay. 2.105 B16F10 cells transfec-
ted with siRNA Control or siRNA Jam-c were labeled with PKH26
red-ﬂuorescent linker kit (SIGMA) according to manufacturer’s
protocol and cocultured for 1 h with LMEC cells. Plates were
washed 3 times with PBS. Adhesion was quantiﬁed as described
above following ﬂuorescents cells.
2.7. In vivo metastasis assay
B16F10 cells (2.105 cells/mouse) were injected i.v. in Jam-b+/+ or
Jam-b/ mice. Mice were sacriﬁced 14 days after and lung re-
moved in PFA 4%.
2.8. Histology, haematoxylin and eosin staining and imaging
For histological study, lungs were ﬁxed in 4% buffered formalin
and embedded in parafﬁn. 5 lm thick lung sections were stained
with haematoxylin and eosin as described previously [14]. Images
were obtained on a Leica DMD 108 photomicroscope.
For cryosections, lungs were inﬂated with OCT before embed-
ding. 7 lm Lung were ﬁxed in methanol (5 mn, 220 C), dried,
and rehydrated in PBS with 0.5% BSA before processing for immu-
nostaining. Primary antibodies against PECAM-1 (GC51, rat anti-
mouse IgG2b), JAM-B (polyclonal rabbit anti-mouse p829), alpha
smooth muscle actin (aSMA, SIGMA) were used for immunoﬂuo-
rescent stainings. Immunohistochemistry was performed as previ-
ously described [12]. All images were obtained using a Zeiss
LSM510 Meta confocal microscope.
2.9. Statistical analysis
Statistical signiﬁcance was determined with non-parametric
Mann–Withney U test or one way ANOVA with Bonferroni post-
test using the Prism software.
3. Results
3.1. Lung endothelial cells express JAM-B
Since JAM-B has been reported to be heterogeneously expressed
by different vascular beds [15–17], we ﬁrst wondered if JAM-B was
expressed by the lung vasculature. As shown in Fig 1, we found
that JAM-B was detectable in murine lungs and was partially colo-
calized with PECAM-1, demonstrating that lung endothelial cells
express JAM-B. Of note, JAM-B expression was prominent on large
and medium vessels, while smaller capillaries did not expressed
JAM-B. This is consistent with previous reports showing that
Jam-b mRNA is absent from small caliber arterioles of the lungs
and is induced in sites adjacent to foci of inﬂammation [10].
3.2. B16F10 melanoma cells interact with JAM-B in a JAM-C dependent
manner
To further validate our experimental model, we tested whether
B16F10 cells express JAM-C and bind to the recombinant soluble
protein JAM-B (sol-JAM-B). We found that the recombinant
soluble form of JAM-B binds to B16F10 cells while a recombinant
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Fig. 4. JAM-C down-regulation prevents B16F10 cell homing into the lungs. (A) B16F10 siRNA Control and B16F10 siRNA Jam-c cells were stained, respectively, with PKH26
red and PKH67 green ﬂuorescent dyes and mixed in a 1:1 ratio. The dot-plot shows one representative proﬁle of the mix used for i.v injection (B) One representative ﬂow
cytometry proﬁle obtained from the lungs of uninjected mice is shown. (C) Left panel: One representative ﬂow cytometry proﬁle obtained from dissociated lungs of mice
injected with the 1:1 mixture of B16F10 siRNA Control and B16F10 siRNA Jam-c cells stained respectively with PKH26 and PKH67 is shown. Mice were sacriﬁced 3 after the
injection and B16F10 cell migration in the lung was quantiﬁed by FACS. Middle panel: Histogram showing the quantiﬁcation of homing experiments. Results are expressed as
ratios of PKH67/PKH26 positive events recovered from the lungs after 3 h as compared to ratio of injected cells. n = 6, one representative experiment out of three is shown.
Right panel: histogram showing results obtained from the pool of three experiments. Ratio of injected cells is normalized to 1. n = 15 mice/experimental group. ⁄⁄⁄, p < 0.001.
(D–F) same as in (A–C) except that experiments were performed in Jam-b deﬁcient mice. The loss of differential retention of B16F10 siRNA Control as compared to B16F10
siRNA Jam-c in these animals as compared to control mice indicates that JAM-B is used as a ligand for JAM-C expressed by melanoma cells under these experimental
conditions. Histogram show the results obtained from the pool of two experiments. n = 7 mice/experimental group.
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partially dependent on JAM-C expression by melanoma cells since
a monoclonal antibody directed against JAM-C decreased eight fold
the binding of sol-JAM-B to B16F10 as compared to control
(Fig. 2A). This was not due to the loss of JAM-C expression on the
surface of B16F10 cells since the cell surface expression detected
with a polyclonal antibody against JAM-C remained unchanged
(Fig. 2B).3.3. JAM-C mediates adhesion of B16F10 cells to lung endothelial cells
Having shown that the B16F10 express JAM-C as a cognate
receptor for JAM-B, we addressed the question whether JAM-B/
JAM-C interaction was functional. Using static adhesion assay, we
found that B16F10 cells selectively adhered to sol-JAM-B. In
contrast, adhesion to the recombinant soluble protein JAM-C was
not detected under these experimental conditions (Fig. 3A). We
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Fig. 5. B16F10 metastasis dissemination in Jam-b deﬁcient mice. (A) Pictures
showing the pattern of expression of PECAM-1 (red), JAM-B (green), and DAPI (blue)
on lung cryosections. The merge picture shows partial colocalization between JAM-
B and PECAM-1 staining on lung vessel. (B) Pictures showing the loss of JAM-B
expression on vessels in Jam-b deﬁcient mice, while PECAM staining appears
unaffected. (C) Representative macroscopic pictures of the lungs of B16F10 injected
in Jam-b+/+ (left panel) and Jam-b/ mice (right panel). Pictures are representative
of two different mice from two independent experiments. (D) Quantiﬁcation of
metastasis by lung sections of Jam-b+/+ (white) or Jam-b/ (black) B16F10 injected
mice. Results are obtained from pictures of three independent high power ﬁelds
from lung sections of two different mice from two independent experiments. (E)
Representative pictures of haematoxylin/eosin staining of lung sections used for
quantiﬁcation in (D). ⁄, p < 0.05.
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microvascular endothelial cells (LMECs) which expressed JAM-B
(Fig. 3B), could be JAM-C dependent. To this end, we used siRNA
to downregulate Jam-c expression on B16F10 cells (Fig. 3C) and
compared adhesion of B16F10 cells manipulated for JAM-C expres-
sion to LMECs. As shown in Fig. 3D, we found that adhesion ofB16F10 cells lacking JAM-C expression (siRNA Jam-c) to LMECs
was reduced by more than 50% as compared to control B16F10
cells (siRNA ctrl) indicating that JAM-C plays a role in the adhesion
of B16F10 cells to lung endothelial cells.
3.4. JAM-B is used as a counter-receptor for JAM-C-mediated homing
of B16F10 cells to the lungs
To get further insights into the function of JAM-C expressed on
melanoma cells, we performed short term homing assays of genet-
ically engineered B16F10 cells into the lungs. For this purpose,
B16F10 silenced for Jam-c expression (B16F10 siRNA Jam-c) were
stained with PKH67 and mixed with control B16F10 cells
(B16F10 siRNA ctrl) stained with PKH26 before intravenous injec-
tion to mice at a ratio 1:1 (Fig. 4A). Three hours after injection,
lungs were removed and digested with collagenase before ﬂow
cytometry analysis. Mice that did not receive ﬂuorescent cells were
used as negative control (Fig. 4B). Under these experimental condi-
tions, any changes in the ratios between PKH67 and PKH26 stained
cells recovered from the lungs indicate changes in the lung homing
properties of the cells. We found that, compared to the quantity of
B16F10 siRNA ctrl cells, less B16F10 siRNA Jam-c cells were found
in the lung after 3 h as demonstrated by the decreased ratio of
PKH67 over PKH 26 positive cells (Fig. 4C). This indicates that
JAM-C contributes to migration, short term adhesion or retention
of B16F10 in the lungs. In order to test whether this effect was
dependent on JAM-B expression in the lungs, the same experiment
was then repeated in Jam-b deﬁcient mice (Fig. 4D–F). The loss of
JAM-B expression in the lung abolished the differential migration
of JAM-C expressing cells versus Jam-c silenced cells indicating that
JAM-B is used as a counter-receptor for JAM-C mediated retention
of melanoma cells in the lungs.
3.5. B16F10 cell metastatic potential is reduced in jam-b/ mice
To evaluate if the differential retention of B16F10 mediated by
JAM-B/JAM-C interaction may translate into a differential meta-
static potential of the cells, we performed metastasis experiments
using Jam-b deﬁcient mice in which JAM-B expression associated
to lung vessels is abolished (Fig. 5A–B). To this end, B16F10 mela-
noma cells were injected intravenously into Jam-b+/+ or Jam-b/
mice and lung metastasis was analyzed after two weeks. As shown
in Fig. 5C, Jam-b/ mice exhibited fewer metastasis as compared
to control mice. The microscopic counting and quantiﬁcation of
metastasis on lung sections conﬁrmed a more than twofold de-
crease in the number of metastasis in Jam-b/ mice as compared
to controls (Fig. 5D). This was accompanied by a decrease in the
size of metastasis (Fig. 5E) indicating that JAM-B expression on
endothelial cells contributes to the overall degree of metastasis.4. Discussion
In this study we have demonstrated for the ﬁrst time that JAM-B
expressed by endothelial cells contributes to JAM-C dependent
hematogenous lung melanoma metastasis. Our study extends the
ﬁndings by H. F. Langer and collaborators who have recently re-
ported a function for JAM-C in hematogenous B16 melanoma dis-
semination through homotypic JAM-C/JAM-C interaction [6].
We show that JAM-C expressed by melanoma cells contributes
to adhesion of tumor cells to JAM-B expressing lung endothelial
cells in vitro. Whether endothelial JAM-B is used as the counter-
receptor for JAM-C in this experimental model remains unclear,
but our observation that lung trapping of B16F10 cells depends
on JAM-B expression in the lung and JAM-C expression by
melanoma cells strongly suggests that melanoma metastasis is
M.-L. Arcangeli et al. / FEBS Letters 586 (2012) 4046–4051 4051controlled by JAM-B/JAM-C interaction in addition to JAM-C/JAM-C
interaction [6].
This would be consistent with the model of hematogenous tu-
mor cell dissemination occuring through a coordinated process
similar to leukocyte migration from blood to tissues. This involves
rolling, adhesion and transmigration of leukocytes across the vas-
cular layer in which JAM-C has been extensively involved [18–
21]. The current picture is that JAM-C expressed by endothelial
cells controls the ﬁnal step of leukocyte transendothelial migration
through its expression at lateral cell–cell border between neigh-
boring endothelial cells. However a lot less is known about the
function of JAM-C expressed on leukocyte in this process, most
likely due to the fact that JAM-C is not expressed on mature mouse
leukocytes while it is expressed on subsets of human leukocytes.
With respect to JAM-C expression on transmigrating cells, the
study of melanoma metastasis brings new insights into the molec-
ular mechanisms involving JAM-C in transendothelial migration.
Two independent studies have shown that JAM-C expressed on
melanoma cells contributes to the ﬁnal step of melanoma transen-
dothelial migration but is not involved in adhesion of melanoma
cells to endothelial cells [6,22]. This somehow differs from the
results obtained in the present study but is easily explained by
differences on the endothelial cells used in the different studies.
H. Langer and colleagues have used the b.End3 murine endothelial
cell line which expresses little or no JAM-B as a model for B16/
endothelial interactions in vitro. Under these conditions, JAM-C
expressed on melanoma cells engages trans-interaction with
JAM-C to achieve the ﬁnal step of transendothelial migration. In
the present study, we have used primary lung endothelial cells that
express high amount of JAM-B but little or no JAM-C (not shown).
This allows revealing the contribution of JAM-B/JAM-C interaction
to the adhesion step of melanoma cell interaction with lung endo-
thelial cells. This would be in agreement with a model in which the
adhesion step, that precedes transendothelial migration, is con-
trolled by the engagement of JAM-C with JAM-B on endothelial
cells while the transmigration step involves JAM-C/JAM-C interac-
tion [6–8,10,13,23].
The recent ﬁnding that JAM-C exists as soluble form in inﬂam-
matory biological ﬂuid has added an additional level of complexity
in our understanding of the interaction network mediated by JAM-
C [24]. Indeed, inﬂammation has often been associated with cancer
progression [25] and one could not exclude that the soluble form of
JAM-C contributes to metastasis. We and others have previously
shown that the recombinant soluble form of JAM-C binds with
higher afﬁnity to JAM-B than JAM-C and could be used as antago-
nist of JAM-C/JAM-C or JAM-C/JAM-B interactions in vivo [6,12,26].
However, high concentrations of soluble molecules are often used
in such experiments in order to saturate the ligands. Therefore one
could not exclude that chronic inﬂammation results in low levels
of circulating soluble JAM-C that will preferentially bind to its high
afﬁnity ligand, JAM-B, but not JAM-C. In that case, the pro-adhesive
function of JAM-B/JAM-C interaction will be partially impaired
while the transendothelial transmigration event mediated by
JAM-C/JAM-C interaction will remain unaffected by low levels of
circulating soluble JAM-C. Although, such a scenario remains to
be tested, it seems required to address these issues before drawing
the best suited strategy to use antagonization of JAM-C interac-
tions as adjuvant therapy to prevent melanoma metastasis.
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